Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for Innovative Drug HSK51155 Tablets

Haisco Pharmaceutical Group Co., Ltd.·August 6, 2026·2 pages

✨ AI Summary

HSK51155, an innovative oral small molecule analgesic developed by the company, has received approval from the NMPA for clinical trials. The drug is intended for migraine treatment and aims to provide a safer and more effective option. The company has granted AbbVie exclusive global rights outside of Greater China for over $700 million.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002653

Stock Abbreviation: HSK

Announcement No.: 2026-084

Hengrui Medicine Group Co., Ltd.

Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for Innovative Drug HSK51155 Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or material omissions.

Hengrui Medicine Group Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and the relevant situation is hereby announced as follows:

| Drug Name | Dosage Form | Application Item | New Drug Registration Classification | |---|---|-

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.